Why ClotTriever is a “gamechanger” for the treatment of deep vein thrombosis

1283

Andrew Wigham (Oxford, UK) and Rick De Graaf (Friedrichshafen, Germany) discuss the current state of deep vein thrombosis (DVT) treatment at the Leipzig Interventional Course (LINC) 2022 (6–9 June, Leipzig, Germany), with both noting that “a massive problem” in Europe is the lack of awareness around treatment.

Wigham highlights some of the major challenges associated with treating this patient population, including that “traditional devices have a limited window of effective treatment of acute DVT”, as well as “limited operating room time and bed availability” due to the COVID-19 pandemic, and “significant bleeding risk to the patient” with thrombolysis. “We are really in need of solutions to address these issues”, he adds.

“We do not want to do thrombolysis anymore,” states De Graaf, when questioned on his preferred treatment modality. “We went through all the devices out there and my major problem was always that I could not get all the thrombus out,” he says, adding that “thankfully now I am finally very confident that I have a device [ClotTriever, Inari Medical] that takes out all the thrombus.” Wigham himself adds that ClotTriever is “a very effective device that helps us to clear the thrombus and potentially limit the amount of stents we are using in a young patient cohort.”

Wigham goes on to say that one of the principle advantages of the device is that he has found it to be “effective out beyond six weeks”. De Graaf adds that this is “a huge benefit that we see as well”, with the pair concluding that the device is a real “gamechanger” for the treatment of DVT.

This video is sponsored by Inari Medical.

Rick de Graaf and Andrew Wigham will be sharing their experiences with ClotTriever® for the treatment of deep vein thrombosis during the Inari symposium at CIRSE 2022 (Sunday, 11th September, 1pm2pm, room 114).


LEAVE A REPLY

Please enter your comment!
Please enter your name here